Hematopoietic augmentation by a β-(1,4)-linked mannan

Stefan F. Egger, Gregory S. Brown, Linda S. Kelsey, Kenneth M. Yates, Larry J. Rosenberg, James E Talmadge

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

CARN 750 (injectable acemannan) is a polydispersed β-(1,4)-linked acetylated mannan isolated from the Aloe barbadensis plant. It has multiple therapeutic properties including activity in wound repair and as a biological agent for the treatment of neoplasia in animals as well as the ability to activate macrophages. We report herein that CARN 750 directly or indirectly has significant hematoaugmenting properties. We observed that the subcutaneous administration of CARN 750 significantly increases splenic and peripheral blood cellularity, as well as hematopoietic progenitors in the spleen and bone marrow as determined by the interleukin-3-responsive colony-forming unit culture assay and the high-proliferative-potential colony-forming-cell (HPP-CFC) assay (a measure of primitive hematopoietic precursors) in myelosuppressed (7 Gy) C57BL/6 mice. The greatest hematopoietic effect was observed following sublethal irradiation in mice receiving 1 mg CARN 750/animal, with less activity observed at higher or lower doses. Further, CARN 750, following daily injection, has activity equal to or greater than the injection of an optimal dose of granulocyte-colony-stimulating factor (G-CSF) in myelosuppressed mice. In this comparison, significantly greater activity was observed in the splenic and peripheral blood cellularity, and in the frequency and absolute number of splenic HPP-CFC as compared to the mice receiving G-CSF at 3 μg/animal. CARN 750, when administered to myelosuppressed animals, decreased the frequency of lymphocytes with a concomitant significant increase in the frequency of polymorphonuclear leukocytes (PMN). However, owing to the increased cellularity, a significant increase in the absolute number of PMN, lymphocytes, monocytes and platelets was observed, suggesting activity on multiple cell lineages. The latter is the primary difference in activity as compared to G-CSF which has activity predominantly on PMN.

Original languageEnglish (US)
Pages (from-to)195-205
Number of pages11
JournalCancer Immunology Immunotherapy
Volume43
Issue number4
DOIs
StatePublished - Dec 1 1996

Fingerprint

Mannans
Granulocyte Colony-Stimulating Factor
Neutrophils
Injections
Colony-Forming Units Assay
Lymphocytes
Aloe
Interleukin-3
Biological Factors
Cell Lineage
acemannan
Inbred C57BL Mouse
Monocytes
Blood Platelets
Spleen
Bone Marrow
Macrophages
Wounds and Injuries
Therapeutics

Keywords

  • CFU-C
  • G-CSF
  • HPP-CFC
  • acetylated mannan
  • hematopoiesis
  • myelosuppression

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Egger, S. F., Brown, G. S., Kelsey, L. S., Yates, K. M., Rosenberg, L. J., & Talmadge, J. E. (1996). Hematopoietic augmentation by a β-(1,4)-linked mannan. Cancer Immunology Immunotherapy, 43(4), 195-205. https://doi.org/10.1007/s002620050322

Hematopoietic augmentation by a β-(1,4)-linked mannan. / Egger, Stefan F.; Brown, Gregory S.; Kelsey, Linda S.; Yates, Kenneth M.; Rosenberg, Larry J.; Talmadge, James E.

In: Cancer Immunology Immunotherapy, Vol. 43, No. 4, 01.12.1996, p. 195-205.

Research output: Contribution to journalArticle

Egger, SF, Brown, GS, Kelsey, LS, Yates, KM, Rosenberg, LJ & Talmadge, JE 1996, 'Hematopoietic augmentation by a β-(1,4)-linked mannan', Cancer Immunology Immunotherapy, vol. 43, no. 4, pp. 195-205. https://doi.org/10.1007/s002620050322
Egger, Stefan F. ; Brown, Gregory S. ; Kelsey, Linda S. ; Yates, Kenneth M. ; Rosenberg, Larry J. ; Talmadge, James E. / Hematopoietic augmentation by a β-(1,4)-linked mannan. In: Cancer Immunology Immunotherapy. 1996 ; Vol. 43, No. 4. pp. 195-205.
@article{ab2ccdcd31fb4cb58f258187861d8411,
title = "Hematopoietic augmentation by a β-(1,4)-linked mannan",
abstract = "CARN 750 (injectable acemannan) is a polydispersed β-(1,4)-linked acetylated mannan isolated from the Aloe barbadensis plant. It has multiple therapeutic properties including activity in wound repair and as a biological agent for the treatment of neoplasia in animals as well as the ability to activate macrophages. We report herein that CARN 750 directly or indirectly has significant hematoaugmenting properties. We observed that the subcutaneous administration of CARN 750 significantly increases splenic and peripheral blood cellularity, as well as hematopoietic progenitors in the spleen and bone marrow as determined by the interleukin-3-responsive colony-forming unit culture assay and the high-proliferative-potential colony-forming-cell (HPP-CFC) assay (a measure of primitive hematopoietic precursors) in myelosuppressed (7 Gy) C57BL/6 mice. The greatest hematopoietic effect was observed following sublethal irradiation in mice receiving 1 mg CARN 750/animal, with less activity observed at higher or lower doses. Further, CARN 750, following daily injection, has activity equal to or greater than the injection of an optimal dose of granulocyte-colony-stimulating factor (G-CSF) in myelosuppressed mice. In this comparison, significantly greater activity was observed in the splenic and peripheral blood cellularity, and in the frequency and absolute number of splenic HPP-CFC as compared to the mice receiving G-CSF at 3 μg/animal. CARN 750, when administered to myelosuppressed animals, decreased the frequency of lymphocytes with a concomitant significant increase in the frequency of polymorphonuclear leukocytes (PMN). However, owing to the increased cellularity, a significant increase in the absolute number of PMN, lymphocytes, monocytes and platelets was observed, suggesting activity on multiple cell lineages. The latter is the primary difference in activity as compared to G-CSF which has activity predominantly on PMN.",
keywords = "CFU-C, G-CSF, HPP-CFC, acetylated mannan, hematopoiesis, myelosuppression",
author = "Egger, {Stefan F.} and Brown, {Gregory S.} and Kelsey, {Linda S.} and Yates, {Kenneth M.} and Rosenberg, {Larry J.} and Talmadge, {James E}",
year = "1996",
month = "12",
day = "1",
doi = "10.1007/s002620050322",
language = "English (US)",
volume = "43",
pages = "195--205",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Hematopoietic augmentation by a β-(1,4)-linked mannan

AU - Egger, Stefan F.

AU - Brown, Gregory S.

AU - Kelsey, Linda S.

AU - Yates, Kenneth M.

AU - Rosenberg, Larry J.

AU - Talmadge, James E

PY - 1996/12/1

Y1 - 1996/12/1

N2 - CARN 750 (injectable acemannan) is a polydispersed β-(1,4)-linked acetylated mannan isolated from the Aloe barbadensis plant. It has multiple therapeutic properties including activity in wound repair and as a biological agent for the treatment of neoplasia in animals as well as the ability to activate macrophages. We report herein that CARN 750 directly or indirectly has significant hematoaugmenting properties. We observed that the subcutaneous administration of CARN 750 significantly increases splenic and peripheral blood cellularity, as well as hematopoietic progenitors in the spleen and bone marrow as determined by the interleukin-3-responsive colony-forming unit culture assay and the high-proliferative-potential colony-forming-cell (HPP-CFC) assay (a measure of primitive hematopoietic precursors) in myelosuppressed (7 Gy) C57BL/6 mice. The greatest hematopoietic effect was observed following sublethal irradiation in mice receiving 1 mg CARN 750/animal, with less activity observed at higher or lower doses. Further, CARN 750, following daily injection, has activity equal to or greater than the injection of an optimal dose of granulocyte-colony-stimulating factor (G-CSF) in myelosuppressed mice. In this comparison, significantly greater activity was observed in the splenic and peripheral blood cellularity, and in the frequency and absolute number of splenic HPP-CFC as compared to the mice receiving G-CSF at 3 μg/animal. CARN 750, when administered to myelosuppressed animals, decreased the frequency of lymphocytes with a concomitant significant increase in the frequency of polymorphonuclear leukocytes (PMN). However, owing to the increased cellularity, a significant increase in the absolute number of PMN, lymphocytes, monocytes and platelets was observed, suggesting activity on multiple cell lineages. The latter is the primary difference in activity as compared to G-CSF which has activity predominantly on PMN.

AB - CARN 750 (injectable acemannan) is a polydispersed β-(1,4)-linked acetylated mannan isolated from the Aloe barbadensis plant. It has multiple therapeutic properties including activity in wound repair and as a biological agent for the treatment of neoplasia in animals as well as the ability to activate macrophages. We report herein that CARN 750 directly or indirectly has significant hematoaugmenting properties. We observed that the subcutaneous administration of CARN 750 significantly increases splenic and peripheral blood cellularity, as well as hematopoietic progenitors in the spleen and bone marrow as determined by the interleukin-3-responsive colony-forming unit culture assay and the high-proliferative-potential colony-forming-cell (HPP-CFC) assay (a measure of primitive hematopoietic precursors) in myelosuppressed (7 Gy) C57BL/6 mice. The greatest hematopoietic effect was observed following sublethal irradiation in mice receiving 1 mg CARN 750/animal, with less activity observed at higher or lower doses. Further, CARN 750, following daily injection, has activity equal to or greater than the injection of an optimal dose of granulocyte-colony-stimulating factor (G-CSF) in myelosuppressed mice. In this comparison, significantly greater activity was observed in the splenic and peripheral blood cellularity, and in the frequency and absolute number of splenic HPP-CFC as compared to the mice receiving G-CSF at 3 μg/animal. CARN 750, when administered to myelosuppressed animals, decreased the frequency of lymphocytes with a concomitant significant increase in the frequency of polymorphonuclear leukocytes (PMN). However, owing to the increased cellularity, a significant increase in the absolute number of PMN, lymphocytes, monocytes and platelets was observed, suggesting activity on multiple cell lineages. The latter is the primary difference in activity as compared to G-CSF which has activity predominantly on PMN.

KW - CFU-C

KW - G-CSF

KW - HPP-CFC

KW - acetylated mannan

KW - hematopoiesis

KW - myelosuppression

UR - http://www.scopus.com/inward/record.url?scp=0030481584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030481584&partnerID=8YFLogxK

U2 - 10.1007/s002620050322

DO - 10.1007/s002620050322

M3 - Article

C2 - 9003464

AN - SCOPUS:0030481584

VL - 43

SP - 195

EP - 205

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -